# psoriasis - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 20224
- Completion tokens: 14281
- Reasoning tokens: 0
- Total tokens: 34505
- API requests reported: 1
- Elapsed seconds: 50.662
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

This dataset provides a transcriptomic profile comparing psoriatic lesional skin against normal control skin (100 differentially expressed genes: 90 upregulated, 10 downregulated). The global transcriptional changes reflect four primary, interconnected pathological processes:

1. **Epidermal Hyperproliferation and Dysregulated Barrier Remodeling**: Heavy induction of small proline-rich proteins (SPRR family), late cornified envelope proteins (LCE family), stress keratins (*KRT6A*), and gap junction channels (*GJB2*, *GJB6*) demonstrates severe keratinocyte hyperproliferation and altered terminal differentiation.
2. **Amplified IL-36 / IL-20 Inflammatory Axis and Innate Alarmin Cascade**: Massive upregulation of IL-36 family cytokines (*IL36A*, *IL36G*), IL-20 family cytokines (*IL19*, *IL20*, *IL26*), antimicrobial defensins (*DEFB4A*, *DEFB4B*, *DEFB103A*, *DEFB103B*), and S100 alarmins (*S100A7*, *S100A7A*, *S100A8*, *S100A12*) drives sustained localized inflammatory feedback loops.
3. **Epithelial Protease and Antiprotease Imbalance**: Co-elevation of transmembrane serine proteases (*TMPRSS11D*, *KLK13*, *PRSS27*) alongside cytosolic/secreted clade B serpins (*SERPINB3*, *SERPINB4*, *SERPINB11*, *SERPINB13*) and elafin (*PI3*) indicates an active counter-regulatory attempt to control stratum corneum desquamation and proteolysis.
4. **Metabolic Adaptation and Downregulation of Homeostatic Growth Signals**: Upregulation of lipid, retinoid, and aldehyde metabolism pathways (*AKR1B10*, *AKR1B15*, *FABP5*, *PLA2G4D*, *KYNU*) coincides with marked downregulation of homeostatic EGF family ligands (*BTC*, log2FC = -4.299) and cytochrome P450 enzymes (*CYP2W1*, log2FC = -4.704).

---

### 2. Core Biological Programs

#### Program 1: Keratinocyte Cornification & Epidermal Barrier Remodeling
* **Direction**: Upregulated
* **Major Supporting Genes**: *SPRR2A* (log2FC = 7.312, FDR = 2.93e-85), *SPRR2B* (log2FC = 6.380, FDR = 4.03e-79), *SPRR2D* (log2FC = 5.920, FDR = 8.03e-77), *SPRR3* (log2FC = 7.180, FDR = 1.80e-70), *LCE3A* (log2FC = 8.298, FDR = 1.42e-64), *LCE3D* (log2FC = 5.314, FDR = 1.82e-63), *KRT6A* (log2FC = 4.303, FDR = 9.86e-68), *GJB2* (log2FC = 4.419, FDR = 1.74e-86), *GJB6* (log2FC = 3.018, FDR = 1.64e-69).
* **Standardized Pathway**: Reactome *Formation of the cornified envelope* (R-HSA-6809371); GO *Epidermis Development* (GO:0008544).
* **Biological Explanation**: The coordinated induction of envelope precursors (SPRR and LCE families) combined with stress-activated keratins (*KRT6A*) and intercellular gap junction subunits (*GJB2*, *GJB6*) reflects the abnormal keratinization, acanthosis, and defective envelope cross-linking characteristic of psoriatic plaques.
* **Evidence Strength & Limitations**: High direct input statistical significance supported by Reactome/GO annotations. *Limitation*: Bulk tissue statistics cannot separate intrinsic keratinocyte gene induction from hyperplastic epidermal expansion (cell-type composition bias).

#### Program 2: Interleukin-36 and IL-20 Pro-Inflammatory Cytokine Signaling
* **Direction**: Upregulated
* **Major Supporting Genes**: *IL36A* (log2FC = 11.374, FDR = 1.65e-98), *IL36G* (log2FC = 5.684, FDR = 1.43e-90), *IL36RN* (log2FC = 3.005, FDR = 3.85e-62), *IL19* (log2FC = 7.580, FDR = 9.04e-84), *IL20* (log2FC = 5.667, FDR = 2.85e-71), *IL26* (log2FC = 4.361, FDR = 3.79e-65), *IRAK2* (log2FC = 2.083, FDR = 9.74e-62), *TNIP3* (log2FC = 7.279, FDR = 2.82e-83), *ZC3H12A* (log2FC = 3.848, FDR = 2.49e-71).
* **Standardized Pathway**: KEGG *IL-17 signaling pathway*; Reactome *Interleukin-20 family signaling* (R-HSA-8854691); KEGG *Cytokine-cytokine receptor interaction*.
* **Biological Explanation**: IL-36 (*IL36A*, *IL36G*) and IL-20 family members (*IL19*, *IL20*, *IL26*) act as central upstream drivers in cutaneous inflammation. Their elevation activates IRAK2-mediated NF-κB/MAPK signaling, inducing downstream alarmins while triggering negative feedback modulators (*IL36RN*, *TNIP3*, *ZC3H12A*).
* **Evidence Strength & Limitations**: Extremely high magnitude upregulation (up to >2000-fold linear increase); confirmed by KEGG/Reactome pathway recurrence. *Limitation*: Transcript abundance does not confirm post-translational enzymatic processing required for IL-36 activation.

#### Program 3: Innate Antimicrobial Defense & Alarmin Secretion
* **Direction**: Upregulated
* **Major Supporting Genes**: *DEFB4A* (log2FC = 11.183, FDR = 2.18e-69), *DEFB4B* (log2FC = 11.031, FDR = 3.70e-71), *DEFB103A* (log2FC = 5.758, FDR = 5.76e-68), *DEFB103B* (log2FC = 5.751, FDR = 1.86e-68), *S100A12* (log2FC = 8.329, FDR = 7.94e-97), *S100A7A* (log2FC = 9.833, FDR = 9.25e-63), *S100A7* (log2FC = 7.095, FDR = 3.49e-62), *S100A8* (log2FC = 7.729, FDR = 6.05e-66), *GPR15LG* (log2FC = 5.516, FDR = 2.51e-77).
* **Standardized Pathway**: GO *Antimicrobial Humoral Response* (GO:0019730); GO *Response To Lipopolysaccharide* (GO:0032496).
* **Biological Explanation**: Activated keratinocytes release beta-defensins and S100 alarmins into the extracellular space, providing antimicrobial barrier protection while acting as chemoattractants for neutrophils and dendritic cells.
* **Evidence Strength & Limitations**: Robust direct statistical evidence and GO annotations. *Limitation*: High sequence homology between duplicated gene pairs (*DEFB4A*/*DEFB4B*, *DEFB103A*/*DEFB103B*) can lead to alignment cross-mapping in short-read sequencing datasets.

#### Program 4: Epithelial Serine Protease & Serpin Antiprotease Regulation
* **Direction**: Upregulated
* **Major Supporting Genes**: *PI3* (log2FC = 9.240, FDR = 1.53e-69), *SERPINB4* (log2FC = 9.118, FDR = 6.68e-66), *SERPINB3* (log2FC = 6.742, FDR = 1.36e-77), *SERPINB11* (log2FC = 4.468, FDR = 1.08e-61), *SERPINB13* (log2FC = 3.095, FDR = 4.09e-67), *TMPRSS11D* (log2FC = 7.749, FDR = 1.49e-82), *KLK13* (log2FC = 4.052, FDR = 2.78e-70), *PRSS27* (log2FC = 4.245, FDR = 1.62e-62).
* **Standardized Pathway**: Reactome *Formation of the cornified envelope* (R-HSA-6809371); GO *Endopeptidase inhibitor activity*.
* **Biological Explanation**: The concurrent induction of transmembrane proteases (*TMPRSS11D*, *KLK13*) and suicide serine protease inhibitors (*SERPINB3*, *SERPINB4*, *PI3*) reflects tight counter-regulation during inflammatory skin turnover, balancing tissue remodeling against tissue destruction.
* **Evidence Strength & Limitations**: Large effect sizes in direct data and strong co-expression networks. *Limitation*: RNA levels do not quantify catalytic activity or serpin-protease complex formation.

#### Program 5: Epidermal Lipid Metabolism & Metabolic Adaptation
* **Direction**: Co-regulated (Enzymes Upregulated, Homeostatic Regulators Downregulated)
* **Major Supporting Genes**: *AKR1B10* (log2FC = 6.265, FDR = 2.35e-89), *AKR1B15* (log2FC = 5.231, FDR = 2.35e-89), *FABP5* (log2FC = 3.645, FDR = 2.76e-81), *PLA2G4D* (log2FC = 4.615, FDR = 2.08e-79), *PLA2G4E* (log2FC = 2.470, FDR = 3.25e-65), *KYNU* (log2FC = 4.416, FDR = 2.00e-91), *VNN3P* (log2FC = 8.283, FDR = 2.63e-146), *BTC* (log2FC = -4.299, FDR = 1.78e-73), *CYP2W1* (log2FC = -4.704, FDR = 7.87e-68).
* **Standardized Pathway**: Reactome *Triglyceride catabolism* (R-HSA-163560); KEGG *Arachidonic acid metabolism*; KEGG *Tryptophan metabolism*.
* **Biological Explanation**: Altered lipid synthesis, fatty acid binding (*FABP5*), lipid aldehyde detoxification (*AKR1B10*), and eicosanoid substrate generation (*PLA2G4D*) support hyperproliferative membrane synthesis, alongside downscaling of baseline metabolic homeostasis (*BTC*, *CYP2W1*).
* **Evidence Strength & Limitations**: Multiple metabolic enzymes altered in the primary table. *Limitation*: Metabolic flux and cellular lipid concentrations cannot be confirmed without lipidomic analysis.

---

### 3. Key Genes and Interaction Modules

1. **IL36A & IL36G Module**
   * **Statistical Direction**: Upregulated (*IL36A*: log2FC = +11.374, FDR = 1.65e-98; *IL36G*: log2FC = +5.684, FDR = 1.43e-90).
   * **Role**: Primary drivers of the inflammatory cytokine cascade (Program 2).
   * **Gene-Gene Relationship**: **Pathway co-membership** (IL-17 and cytokine signaling pathways) and **Direct physical interaction** (both bind receptor subunit IL1RAP, as recorded in STRING/Reactome).
2. **DEFB4A & DEFB4B Module**
   * **Statistical Direction**: Upregulated (*DEFB4A*: log2FC = +11.183, FDR = 2.18e-69; *DEFB4B*: log2FC = +11.031, FDR = 3.70e-71).
   * **Role**: Primary effector antimicrobial peptides (Program 3).
   * **Gene-Gene Relationship**: **Gene duplication paralogs / Pathway co-membership** (antimicrobial response; both interact with CCR6 in STRING records).
3. **SPRR2 Architecture (SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G)**
   * **Statistical Direction**: Upregulated (*SPRR2A*: log2FC = +7.312; *SPRR2B*: log2FC = +6.380; *SPRR2D*: log2FC = +5.920; *SPRR2F*: log2FC = +7.223).
   * **Role**: Structural cornified envelope cross-linking (Program 1).
   * **Gene-Gene Relationship**: **Pathway co-membership** (Formation of the cornified envelope) and **Co-expression** (dense co-expression sub-network in STRING).
4. **S100 Alarmin Module (S100A12, S100A7A, S100A8, S100A7)**
   * **Statistical Direction**: Upregulated (*S100A12*: log2FC = +8.329, FDR = 7.94e-97; *S100A7A*: log2FC = +9.833, FDR = 9.25e-63; *S100A8*: log2FC = +7.729; *S100A7*: log2FC = +7.095).
   * **Role**: Chemotaxis and innate defense (Program 3).
   * **Gene-Gene Relationship**: **Direct physical interaction** (S100A8 forms heterodimers with S100A9; S100A7 interacts with FABP5 in STRING records) and **Pathway co-membership**.
5. **SERPINB3 & SERPINB4 Module**
   * **Statistical Direction**: Upregulated (*SERPINB4*: log2FC = +9.118, FDR = 6.68e-66; *SERPINB3*: log2FC = +6.742, FDR = 1.36e-77).
   * **Role**: Protease inhibition protecting against epidermal degradation (Program 4).
   * **Gene-Gene Relationship**: **Pathway co-membership** (serpin endopeptidase inhibitors) and **Direct physical interaction** with targeted cathepsins (e.g., CTSG in STRING network records).
6. **PI3 (Elafin)**
   * **Statistical Direction**: Upregulated (log2FC = +9.240, FDR = 1.53e-69).
   * **Role**: Dual antiprotease and cornified envelope structural component across Programs 1 and 4.
   * **Gene-Gene Relationship**: **Pathway co-membership** with transglutaminase substrates (*LCE3A*, *SPRR2A*) and serine proteases.
7. **AKR1B10 & AKR1B15 Module**
   * **Statistical Direction**: Upregulated (*AKR1B10*: log2FC = +6.265, FDR = 2.35e-89; *AKR1B15*: log2FC = +5.231, FDR = 2.35e-89).
   * **Role**: Detoxification of lipid peroxidation products and retinoid metabolism (Program 5).
   * **Gene-Gene Relationship**: **Pathway co-membership** (paralogous enzymes in lipid aldehyde reduction).
8. **BTC (Betacellulin)**
   * **Statistical Direction**: Downregulated (log2FC = -4.299, FDR = 1.78e-73).
   * **Role**: Loss of normal EGFR ligand signaling in lesional skin.
   * **Gene-Gene Relationship**: **Regulatory interaction / Pathway co-membership** (EGF receptor signaling pathway).
9. **WAKMAR1 & Non-coding RNA Module**
   * **Statistical Direction**: Downregulated (*WAKMAR1*: log2FC = -5.628, FDR = 2.21e-62) or Upregulated (*LINC01206*: log2FC = +5.494; *LINC01269*: log2FC = +4.768).
   * **Role**: Epigenetic and post-transcriptional regulation of keratinocyte differentiation.
   * **Gene-Gene Relationship**: **Indirect / Putative regulatory relationship** (lncRNA regulation of gene locus architecture or microRNA sponging).
10. **CXCL13 & CXCR2 Axis**
    * **Statistical Direction**: Upregulated (*CXCL13*: log2FC = +5.893, FDR = 9.69e-68; *CXCR2*: log2FC = +2.701, FDR = 9.08e-64).
    * **Role**: Leukocyte recruitment into lesional skin.
    * **Gene-Gene Relationship**: **Pathway co-membership** (chemokine signaling) and **Putative receptor-ligand functional axis**.

---

### 4. Validation Priorities

| Priority Direction | Type | Priority Rationale | Input Evidence | External Evidence | Recommended Next Step | Status |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **IL-36 Cytokine Signaling Axis** | Therapeutic target | Massive induction of *IL36A* and *IL36G* identifies IL-36 as a primary inflammatory driver in psoriatic skin. | Direct upregulation of *IL36A* (+11.37 log2FC), *IL36G* (+5.68 log2FC), and *IRAK2* (+2.08 log2FC). | Clinical trials (ClinicalTrials.gov) and FDA approval of anti-IL-36R monoclonal antibodies (spesolimab). | Neutralization assays in ex vivo psoriatic skin explants monitoring downstream alarmin inhibition (*DEFB4A*, *S100A7*). | **Established evidence** |
| **Protease-Antiprotease Balance** | Mechanistic hypothesis | Co-induction of proteases (*TMPRSS11D*) and antiproteases (*PI3*, *SERPINB4*) suggests active proteolytic remodeling. | *TMPRSS11D* (+7.75 log2FC), *PI3* (+9.24 log2FC), and *SERPINB4* (+9.12 log2FC). | Enzymatic interaction records in UniProt/Reactome; literature on stratum corneum shedding. | Fluorogenic peptide cleavage assays in organotypic 3D skin models to measure net proteolytic activity. | **Supported hypothesis** |
| **Serum / Stratum Corneum Alarmin Panel** | Biomarker | Log2FC values between +7.0 and +11.1 (>200-fold to >2000-fold) make these secreted proteins ideal biomarker candidates. | Extremely low FDR values for *S100A12*, *S100A7A*, *DEFB4A*, and *PI3*. | Protein Atlas (HPA) confirms skin secretion; literature supports correlation with disease severity (PASI score). | ELISA quantification in serum and skin tape-stripping samples from psoriasis patients before and after treatment. | **Supported hypothesis** |
| **AKR1B10 / FABP5 Lipid Detoxification Axis** | Interaction / network hypothesis | Upregulation of *AKR1B10* and *FABP5* indicates metabolic adaptation to lipid peroxidation during hyperproliferation. | Co-induction of *AKR1B10* (+6.27 log2FC), *FABP5* (+3.65 log2FC), and *PLA2G4D* (+4.61 log2FC). | Reactome lipid catabolism pathways and STRING co-expression records. | Targeted lipidomic profiling and retinoic acid quantification combined with small-molecule AKR1B10 inhibition. | **Exploratory hypothesis** |
| **Epidermal vs Leukocyte Deconvolution** | Confounding or composition check | Bulk RNA-seq aggregates keratinocytes and infiltrating immune cells (neutrophils, T cells). | Simultaneous elevation of keratinocyte markers (*KRT6A*) and immune receptors (*CXCR2*). | Single-cell RNA-seq literature establishes cell-type-specific compartmentalization. | Single-cell RNA-seq (scRNA-seq) or spatial transcriptomics on paired lesional vs non-lesional skin biopsies. | **Exploratory hypothesis** |

---

### 5. Evidence Grounding

* **Direct Evidence from Input Dataset**: The uploaded differential expression table (log2FC, P value, FDR) provides the direct statistical foundation for all transcriptomic changes. *Note: External statistical validation was not performed on an independent cohort in this analysis.*
* **Pathway / Ontology Evidence**: Standardized annotations from Reactome (*Formation of the cornified envelope*, *IL-20 signaling*), KEGG (*IL-17 signaling pathway*), and GO (*Epidermis development*, *Antimicrobial humoral response*) validate functional module co-regulation.
* **Protein Interaction & Regulatory Evidence**: STRING network records confirm physical interactions (e.g., S100A8–S100A9 heterodimers, IL36A–IL1RAP receptor binding, SERPINB3–CTSG binding) and TRRUST transcriptional regulatory links.
* **Disease-Association & Genetic Evidence**: OpenTargets and GWAS records document genetic risk loci associated with psoriasis in *GJB2*, *IL36RN*, and the *LCE* gene cluster.
* **Expression & Tissue-Specific Evidence**: GTEx and Human Protein Atlas (HPA) confirm strong epidermal skin-specific expression for *KRT6A*, *SPRR* genes, *DEFB* defensins, and *PI3*.
* **Drug & Therapeutic Evidence**: ChEMBL and ClinicalTrials.gov record targeted biologics (e.g., anti-IL-36R antibodies) and retinoid treatments relevant to inflammatory dermatoses.
* **Published Literature Evidence**: PubMed / Europe PMC records (e.g., PMID: 40560938, 42216026) support the pathogenic roles of *KRT6A*, *DEFB4A*, and *S100* alarmins in psoriasis.
* **Evidence Independence & Conflict Note**: Database records (STRING, Reactome, GO, OpenTargets) share underlying genomic annotations and literature sources; they provide complementary biological context rather than independent statistical replication. No major directional conflicts were detected among primary markers.

---

### 6. Limitations and Alternative Explanations

1. **Cell-Composition Bias (Tissue Heterogeneity)**: Psoriatic lesional skin exhibits marked epidermal thickening (acanthosis) and dense leukocyte infiltration. Elevated mRNA levels for keratinocyte markers (*KRT6A*, *SPRR2A*) or neutrophil markers (*S100A12*, *CXCR2*) may reflect shifts in cell-type proportions within bulk biopsies rather than transcript induction per cell. *Investigation*: Perform scRNA-seq, spatial transcriptomics, or digital cell deconvolution (CIBERSORTx).
2. **Absence of External Independent-Cohort Statistical Validation**: External statistical validation was not performed on an independent patient cohort within this analysis context. Transcriptomic effect sizes (log2FC) cannot be assumed to generalize across clinical populations without external cohort replication. *Investigation*: Replicate differential expression analysis in independent public datasets (e.g., GEO datasets GSE52471 or GSE13355).
3. **Association vs. Causation Ambiguity**: High fold changes in downstream effectors (e.g., *VNN3P*, log2FC = 8.283; *SPRR2A*, log2FC = 7.312) may represent reactive epiphenomena downstream of primary cytokines (IL-17A, TNF, IL-36) rather than disease-causing drivers. *Investigation*: Perform CRISPR gene knockout or siRNA knockdown screens in organotypic 3D skin models under cytokine stimulation.
4. **Lack of Protein and Enzymatic Activity Metrics**: Transcript levels for zymogens (*TMPRSS11D*), serpins (*SERPINB3*/*SERPINB4*), or cytokines (*IL36A*) do not guarantee active protein translation, pro-enzyme cleavage, or functional secretion. *Investigation*: Validate results using mass spectrometry proteomics, Western blotting, immunohistochemistry, and substrate cleavage activity assays.
5. **Confounding Clinical and Environmental Variables**: The dataset lacks metadata regarding patient systemic/topical treatment exposure, disease duration, PASI severity scores, or psoriasis subtype (plaque vs. pustular). Prior therapeutic exposure can significantly suppress or alter inflammatory gene signatures. *Investigation*: Stratify future cohorts by treatment-naive status, clinical severity metrics, and disease duration.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=106, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
